Thieme E-Books & E-Journals -
Neuropediatrics, Table of Contents
Neuropediatrics 2021; 52(S 01): S1-S53
DOI: 10.1055/s-0041-1739637
Abstract Salzburg

SUNFISH Part 2: 24-Month Efficacy and Safety of Risdiplam in Patients with Type 2 or Non-Ambulant Type 3 Spinal Muscular Atrophy

Authors

  • M. Oskoui

    1   Departments of Pediatrics and Neurology and Neurosurgery, McGill University, Montreal, Canada

  • J. W. Day

    2   Department of Neurology, Stanford University, Palo Alto, California, United States

  • N. Deconinck

    3   Neuromuscular Reference Center, UZ Gent, Ghent, Belgium
    4   Queen Fabiola Children's University Hospital, ULB, Brussels, Belgium

  • J. Kirschner

    5   Department of Neuropediatrics and Muscle Disorders, Medical Center-University of Freiburg, Freiburg, Germany
    6   Division of Neuropediatrics, Faculty of Medicine, University Hospital Bonn, Bonn, Germany

  • E. Mazzone

    7   Paediatric Neurology and Nemo Center, Catholic University and Policlinico Gemelli, Rome, Italy

  • A. Nascimento

    8   Neuromuscular Unit, Neuropaediatrics Department, Hospital Sant Joan de Déu, Fundacion Sant Joan de Deu, CIBERER – ISC III, Barcelona, Spain

  • K. Saito

    9   Institute of Medical Genetics, Tokyo Women's Medical University, Tokyo, Japan

  • C. Vuillerot

    10   Service de Rééducation Pédiatrique Infantile “L’Escale,” Hôpital Femme Mère Enfant, CHU-Lyon, Université de Lyon, France

  • G. Baranello

    11   The Dubowitz Neuromuscular Centre, NIHR Great Ormond Street Hospital Biomedical Research Centre, Great Ormond Street Institute of Child Health University College London, and Great Ormond Street Hospital Trust, London, United Kingdom
    12   Developmental Neurology Unit, Fondazione IRCCS Istituto Neurologico Carlo Besta, Milan, Italy

  • O. Boespflug-Tanguy

    13   I-Motion - Hôpital Armand Trousseau, Paris, France

  • N. Goemans

    14   Neuromuscular Reference Centre, Department of Paediatrics and Child Neurology, University Hospitals Leuven, Leuven, Belgium

  • A. Kostera-Pruszczyk

    15   Katedra I Klinika Neurologii Warszawskiego Uniwersytetu, Warsaw, Poland

  • L. Servais

    13   I-Motion - Hôpital Armand Trousseau, Paris, France
    16   MDUK Oxford Neuromuscular Centre, Department of Paediatrics, University of Oxford, Oxford, United Kingdom
    17   Reference Center for Neuromuscular Disease, Centre Hospitalier Régional de La Citadelle, Liège, Belgium

  • M. Gerber

    18   Pharma Development Safety, F. Hoffmann-La Roche Ltd, Basel, Switzerland

  • K. Gorni

    19   PDMA Neuroscience and Rare Disease, F. Hoffmann-La Roche Ltd, Basel, Switzerland

  • H. Kletzl

    20   Roche Pharmaceutical Research and Early Development, Roche Innovation Center Basel, Basel, Switzerland

  • C. Martin

    19   PDMA Neuroscience and Rare Disease, F. Hoffmann-La Roche Ltd, Basel, Switzerland

  • R. S. Scalco

    21   Pharma Development Neurology, F. Hoffmann-La Roche Ltd, Basel, Switzerland

  • H. Staunton

    22   Roche Products Ltd, Welwyn Garden City, United Kingdom

  • W. Y. Yeung

    22   Roche Products Ltd, Welwyn Garden City, United Kingdom

  • E. Mercuri

    7   Paediatric Neurology and Nemo Center, Catholic University and Policlinico Gemelli, Rome, Italy
    • ; on behalf of the SUNFISH Working Group
eRefRecommend Article